Qingdao University, China.
Department of Orthodontics, Linyi People's Hospital, China.
J Toxicol Sci. 2021;46(6):255-262. doi: 10.2131/jts.46.255.
Fasudil is an inhibitor of Rhoa/ROCK signaling, which is involved in anti-inflammatory and anti-injury effects. The purpose of this study was to explore the effects of Fasudil on acetaminophen (APAP)-induced liver injury and reveal its potential molecular mechanism. In this study, C57BL/6 J mice were divided into different groups and treated with APAP and specified dose of Fasudil. HE staining was used to detect the changes of liver pathological tissues induced by APAP. ELISA assay was performed to detected the level of related factors. Western blot was used to detect the expressions of Rhoa, ROCK1, ROCK2. CD86 and CD6 were determined by RT-PCR and immunohistochemical staining detected the difference in CD86 expression. Rhoa/ROCK expression was increased in APAP-induced liver injury, and Fasudil targeted the expression of Rhoa/ROCK. Fasudil inhibits APAP-induced hepatic pathological changes and liver function injury. Fasudil inhibits the release of APAP-induced systemic inflammatory factors in liver tissue. Fasudil inhibits the activity of antioxidant enzymes, lipid peroxidation and macrophage infiltration induced by APAP in liver tissues. Fasudil alleviates APAP-induced liver injury via targeting Rhoa/ROCK signal pathway, indicating the possibility for clinical use of Fasudil in APAP-induced liver injury.
法舒地尔是 Rhoa/ROCK 信号通路的抑制剂,参与抗炎和抗损伤作用。本研究旨在探讨法舒地尔对乙酰氨基酚(APAP)诱导的肝损伤的作用,并揭示其潜在的分子机制。在本研究中,C57BL/6J 小鼠被分为不同组,并用 APAP 和特定剂量的法舒地尔处理。HE 染色用于检测 APAP 诱导的肝组织病理变化。ELISA 检测相关因子水平。Western blot 用于检测 Rhoa、ROCK1、ROCK2 的表达。通过 RT-PCR 检测 CD86 和 CD6 的表达,免疫组织化学染色检测 CD86 表达的差异。Rhoa/ROCK 的表达在 APAP 诱导的肝损伤中增加,法舒地尔靶向 Rhoa/ROCK 的表达。法舒地尔抑制 APAP 诱导的肝组织病理变化和肝功能损伤。法舒地尔抑制 APAP 诱导的肝组织中系统性炎症因子的释放。法舒地尔抑制 APAP 诱导的肝组织中抗氧化酶、脂质过氧化和巨噬细胞浸润的活性。法舒地尔通过靶向 Rhoa/ROCK 信号通路缓解 APAP 诱导的肝损伤,表明法舒地尔在 APAP 诱导的肝损伤中的临床应用可能性。
J Pharmacol Sci. 2021-1
Cardiovasc Toxicol. 2020-8
Toxicol Ind Health. 2012-10
Drug Des Devel Ther. 2024
Pharmaceuticals (Basel). 2022-11-19